Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions
Study Details
Study Description
Brief Summary
45 individuals were subdivided into 3 groups, 15 patients with oral premalignant lesions, 15 patients with oral malignant lesions and 15 control individuals. Levels of chemerin and MMP-9 were evaluated in serum and saliva of these subjects utilizing the ELISA technique.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
45 individuals were subdivided into 3 groups, 15 patients suffering from oral premalignant lesions, 15 patients suffering from oral malignant lesions and 15 individuals having age, gender and periodontal status matched with both patients groups acting as a control group. Serum and whole unstimulated saliva samples were collected from all the included groups in order to determine chemerin and MMP-9 in serum and saliva utilizing the ELISA technique.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| oral premalignant patients 15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia. |
|
| oral malignant patients 15 patients suffering from oral malignant lesions |
|
| control subjects 15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease. |
Outcome Measures
Primary Outcome Measures
- salivary levels of chemerin in patients with oral premalignant and malignant lesions. [1 day]
Secondary Outcome Measures
- serum levels of chemerin in patients with oral premalignant and malignant lesions. [1 day]
- serum levels of MMP-9 in patients with oral premalignant and malignant lesions. [morning visit]
- salivary levels of MMP-9 in patients with oral premalignant and malignant lesions. [1 day]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
patients with oral premalignant lesions.
-
patients with oral malignant lesions.
Exclusion Criteria:
- any systemic disease other than oral premalignant or malignant lesions. smokers. pregnant females. periodontal diseases.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Cairo University
Investigators
- Principal Investigator: Noha Ghallab, M.D., Associate Professor of periodontology and Oral Medicine faulty of oral and dental medicine Cairo Unv.
Study Documents (Full-Text)
None provided.More Information
Publications
- Nanda DP, Dutta K, Ganguly KK, Hajra S, Mandal SS, Biswas J, Sinha D. MMP-9 as a potential biomarker for carcinoma of oral cavity: a study in eastern India. Neoplasma. 2014;61(6):747-57. doi: 10.4149/neo_2014_091.
- Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta A, Sozzani S. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007 May 1;109(9):3625-32. Epub 2007 Jan 3.
- Skrzeczyńska-Moncznik J, Stefańska A, Zabel BA, Kapińska-Mrowiecka M, Butcher EC, Cichy J. Chemerin and the recruitment of NK cells to diseased skin. Acta Biochim Pol. 2009;56(2):355-60. Epub 2009 Jun 18.
- Wang N, Wang QJ, Feng YY, Shang W, Cai M. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig. 2014 Apr;18(3):997-1004. doi: 10.1007/s00784-013-1046-8. Epub 2013 Jul 19.
- Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001 Feb;28(2):72-82.
- chemerin_MMP-9_Oral_cancer